Has Ingrid Loma Miller, MD received payments from drug or device companies?

Yes. Drug and device makers reported $363,827 in general payments to Ingrid Loma Miller, MD across 573 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ingrid Loma Miller, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ingrid Loma Miller, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ingrid Loma Miller, MD

Neurology · Norfolk, VANPI 1336393701

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $233,692 of the $363,827 with a category attached, or 64.2%. 15 manufacturers reported payments, led by Biogen at 47.4% of the total. Reporting peaked in 2019 at $132,896 and has fallen 89.0% since, to $14,559 in 2025. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$363,827in general payments, 2019–2025

Across 573 payments — averaging $634.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$172K
Sanofi$44K
EMD Serono, Inc.$37K
AstraZeneca$25K
Genentech USA, Inc.$21K
Bristol Myers Squibb$20K
plus $43K from 9 others

$801,705in research payments, 2019–2025

Across 122 payments — averaging $6571.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$343K
Adamas Pharmaceuticals, Inc.$121K
EMD Serono, Inc.$91K
Genentech, Inc.$82K
Biogen$58K
Roche Products Limited$44K
plus $63K from 4 others

What the payments were for

Consulting fees$80,89322%
Speaking & faculty fees$233,69264%
Travel & lodging$27,9128%
Food & beverage$20,7106%
Education$6200%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	217	$172,347
Sanofi	51	$44,443
EMD Serono, Inc.	74	$37,417
AstraZeneca	46	$24,914
Genentech USA, Inc.	34	$21,251
Bristol Myers Squibb	40	$19,954
E.r. Squibb & Sons, L.L.C.	15	$15,064
Amgen(2 entities)	28	$14,827
Novartis	38	$5,315
F. Hoffmann-la Roche AG	2	$4,877
TG Therapeutics, Inc.	17	$2,735
Genentech, Inc.	8	$557
SK Life Science, Inc.	1	$50
Amneal Pharmaceuticals LLC	1	$43
Mallinckrodt Hospital Products Inc.	1	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TYSABRI$94,702
TECFIDERA$33,788
ZEPOSIA$31,510
Mavenclad$25,929
Vumerity$24,448
AUBAGIO$20,819
OCREVUS$20,520
LEMTRADA$16,768
UPLIZNA$14,182
SOLIRIS$5,821
KESIMPTA$2,308
BRIUMVI$2,279
Ozanimod$519
ULTOMIRIS$373
MAYZENT$343
Ocrevus Zunovo$317
AVONEX$133
GILENYA$123

How this compares

$363,827 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia →

Medicare billing

Part B allowed, 2024

$17,093

Medicare patients

Services billed

199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Teriflunomide	12	$37,831
Glatiramer Acetate	25	$34,725
Nurtec OdtRimegepant Sulfate	11	$19,999
Ajovy SyringeFremanezumab-Vfrm	13	$9,869
Gabapentin	68	$1,731
Cyclobenzaprine Hcl	13	$415
Duloxetine Hcl	21	$361
Tizanidine Hcl	15	$353
Levetiracetam	12	$170
Baclofen	13	$108
Prednisone	11	$41

Paid to pharmacies, not to this prescriber.

Other neurology in Norfolk

Carmen FuentesNorfolk$339K
Tara KimbasonNorfolk$119K
Alice EdwardsNorfolk$111K
Firas BeitinjanehNorfolk$31K
Ramsey FalconerAlexandria$2M
Robert ShinCharlottesville$1.7M
Heidi CraytonVienna$1.5M
Mark LandrioWinchester$631K
Catherine HamRichmond$603K
Jill CramerChristiansburg$598K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →